Snake Antivenom Market 2023-2029
Snake antivenom is a specific type of antivenom used to treat individuals who have been bitten by venomous snakes. When a venomous snake bites a person, it injects venom into the bloodstream through its fangs. This venom can be highly toxic and may cause various symptoms, ranging from local pain, swelling, and tissue damage to more severe systemic effects like paralysis, respiratory distress, and even death.
The global snake
antivenom market size was valued at USD 294.8 million in 2021. The market
is predicted to grow from USD 312.9 million in 2022 to USD 526.0 million by
2029, exhibiting a CAGR of 7.7% during the forecast period.
Global Snake Antivenom Market: Drivers and Restraints:
Snake antivenom is the primary treatment for snakebite
envenomation. It is made by immunizing animals, such as horses or sheep, with
small, non-lethal amounts of snake venom. The animals' immune systems respond
by producing antibodies against the venom. These antibodies are then collected
and purified to create the antivenom.
When administered to a snakebite victim, the antivenom works by
neutralizing the toxic effects of the snake's venom, helping to prevent or
reverse the symptoms of envenomation. The earlier the antivenom is administered
after the snakebite, the more effective it tends to be in mitigating the
effects of the venom.
It is essential to note that snake antivenom is specific to
certain snake species or families. Different venomous snakes have distinct
venoms with unique compositions, so antivenom effectiveness is limited to the
species or group it was produced against. In regions with multiple venomous
snake species, medical professionals must correctly identify the snake
responsible for the bite to administer the appropriate antivenom.
List of Key Companies Operating in Snake Antivenom Market:
- MicroPharm
(U.K.)
- BTG
International Inc. (U.S.)
- VINS Bioproducts
Limited (India)
- Pfizer Inc.
(U.S.)
- SEQIRUS (CSL
Limited) (Australia)
- Inosan Biopharma
(Mexico)
- South Africa
Vaccine Producers (South Africa)
- Rare Disease
Therapeutics, Inc. (U.S.)
- Incepta Vaccine
Ltd. (Bangladesh)
- Bioclon
Institute (Mexico)
Snakebites
are the most neglected health problem in tropical and subtropical regions.
According to the World Health Organization (WHO), globally, an estimated 2.7
million cases of snake envenoming are reported each year. An estimated 81,000
to 138,000 deaths occur each year due to venomous bites. Geographically, there
is a vast disparity in distribution of these encounters.
What is the goal of the report?
- The market
report presents the estimated size of the Snake Antivenom
Market at the end of the forecast period. The report also examines
historical and current market sizes.
- During the
forecast period, the report analyzes the growth rate, market size, and
market valuation.
- The report
presents current trends in the industry and the future potential of the
North America, Asia Pacific, Europe, Latin America, and the Middle East
and Africa markets.
- The report offers
a comprehensive view of the market based on geographic scope, market
segmentation, and key player financial performance.
Furthermore, a detailed study of the competitive landscape of the
Global Snake
Antivenom Market has been given, presenting insights into the company
profiles, financial status, recent developments, mergers and acquisitions, and
the SWOT analysis. This research report will give a clear idea to readers about
the overall Global Snake Antivenom Market scenario to further decide on this market
project.
Related Reports:
Comments
Post a Comment